Clinical Trial Search

Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…

Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001

Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants

Primary: Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause. — NA; 15.1 Months — p=< 0.001

Primary: Percentage of Patients Failure Free at 2 Years Following Study Entry — 36 percentage of participants

Primary: Immunohistochemical Immunoreactive Score Results After 4 Weeks of Sirolimus Compared to Control Specimens — 5.22; 7.44; 4.47; 9.39 score on a scale — p=0.63

Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…

Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants

Primary: Early Disease: Nodule Hardness at 12 Months — 58.1; 61.2 Durometer Arbitrary Units (AU)

Primary: Rate of Disease Progression at 2 Years — 13.8 percentage of participants

Primary: Change in Visible Surface Area of the Lipoma — -31.69; -47.57; -52.42; -66.60 Percent change from baseline

Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs

Primary: Percentage of Participants With Pathological Complete Response (pCR) — 13 percentage of participants

Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)

Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…

Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume

Primary: Correlation Between Ploidy Status With Local Recurrence of Cancer — 3; 31; 14; 92 Participants

Primary: Number of Participants With a Clinical Activity-radiographic Response — 0; 0; 0; 0 Participants

Primary: Safety: Number of Participants With Freedom From Device and Procedure-related Major Adverse Events — 18 Participants — p=0.1309

Primary: Percentage of Responders (Primary Medical Treatment in Arm 1, Primary Surgical Treatment in Arm 2) — 6.7; 50 percentage of participants

Primary: The Incidence of Grade 3 and Grade 4 Adverse Events (AEs) and Defined as Dose-limiting Toxicities (DLTs) in Phase 1 — 0; 0; 0 Participants

Primary: Primary Outcome Measure is Reduction of Flexion Contracture of the Primary Joint. — 91.3; 0 % Joints

Primary: Time to Next Treatment (TNT) — 26.7 months

Primary: Change in Marked Polyp Size — 16; 4; 0 Size of marked polyps

Primary: Percent Change From Baseline in Surface Area of the Lipoma at Six Months — -81.277; 2.053 percentage change from baseline — p=<0.0001

Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants

Primary: Number of Patients Who Survived — 5 Participants

Primary: Number of Subjects With Any FAP-related Event. — 18; 23; 22; 2 Participants — p=0.1210